Trials / Completed
CompletedNCT00043771
Study to Compare the Effects of Two Dosages of Tolvaptan in Congestive Heart Failure Patients
Multi-Center, Double-Blind Study to Compare the Effects of 30mg Qd Versus 15 Mg Bid of Tolvaptan in Congestive Heart Failure Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (planned)
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Patients with congestive heart failure will be assessed for safety and clinical effects of Tolvaptan 30 mg every day versus 15 mg twice a day over a period of 7 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tolvaptan |
Timeline
- Start date
- 2002-05-01
- Completion
- 2002-09-01
- First posted
- 2002-08-14
- Last updated
- 2005-06-24
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00043771. Inclusion in this directory is not an endorsement.